SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gilead Science (GILD) Followers
GILD 121.10+0.4%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Skywatcher who wrote (215)2/19/1997 4:14:00 PM
From: scaram(o)uche   of 961
 
Cost recovery and "market need" largely determine pricing, rather than the quantity of drug in a given formulation. There are exceptions. Crixivan, where patients are receiving 2.4 *grams* per day of a drug that is expensive to manufacture, is one. Pharmaceutical margins are not determined as for commodities........ lower effective doses usually mean higher profits/margins, not lower.

Cheers! Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News